ADOCIA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.42 EUR | +4.34% |
|
-0.36% | -27.04% |
| Apr. 24 | Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 22 | Adocia: announces fund-raising | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.
At the end of 2022, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Calendar
2024-04-28
- LSX World Congress
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.07
EUR
Average target price
9.7
EUR
Spread / Average Target
+20.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.04% | 124M | |
| -2.25% | 103B | |
| +0.79% | 95.71B | |
| +2.01% | 22.02B | |
| -16.60% | 20.9B | |
| -9.03% | 17.85B | |
| -42.83% | 16.21B | |
| -14.93% | 15.52B | |
| +3.39% | 13.86B | |
| +34.17% | 12.04B |
- Stock Market
- Equities
- ADOC Stock
- News Adocia
- Adocia's Phase 2 Study of M1Pram Shows Better Weight Loss, Appetite Control in Diabetic Obese People; Shares Surge 13%
